Appendix 5B Mining exploration entity or oil and gas exploration entityquarterly cash flow report ... 6.1 Payments relate to Director and consulting fees paid to Directors.

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial ...

Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented ...

As stated in our June 2025 Quarterly Activities Report and reaffirmed in the 13 August 2025 Financial and Commercial Update, the Company expects a significant step-up in revenue in FY2026, driven ...